Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liangxue Ointment for VEGFR-TKI Induced Hand-Foot Syndrome
NCT06583369Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Randomised, open-label trial of Liangxue ointment in hand-foot syndrome (HFS) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 2-week treatment effectiveness. Started Mar 2024; status: recruiting.
02
Drugs
Liangxue ointment
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT06583369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583369.